Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 18, 2025
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals held its 21st AGM on July 18, 2025, from 11:00 AM to 11:57 AM via video conferencing, with 111 shareholders attending and corporate/institutional members representing 48.14% of paid-up equity capital participating. This was the company's first AGM after its successful IPO and dual listing on NSE and BSE. Chairman and MD Sandeep Jain highlighted a landmark CDMO contract worth approximately EUR 200 million with a global pharma leader for the European market, expansion of manufacturing facilities at Haridwar (Injectables), Kotdwar and Baddi, and R&D spend of Rs 130 crore yielding 31 DCGI and 117 FSSAI approvals. The company also strengthened in-licensing partnerships with Triple Hair Inc. (Canada) and Caregen (South Korea), and now operates 14 manufacturing facilities (11 formulations + 3 API) with 3 R&D centres. Five ordinary resolutions were tabled, including adoption of FY25 financial statements, re-appointment of Sanjeev Jain, appointment of secretarial auditors for FY26-FY30, cost auditor remuneration ratification, and appointment of Anil Amin as Independent Director; voting was conducted via remote e-voting and e-voting during the meeting.
Mostly procedural with positive business commentary. The first post-IPO AGM reassures investors on growth momentum (EUR 200M CDMO deal, capacity expansion, R&D approvals) and governance continuity, though no new dividend or buyback was announced. The resolutions are largely routine and expected to pass comfortably given the 48% institutional participation already recorded.